This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Articles

Buspirone in the Management of Anxiety and Irritability in Children With Pervasive Developmental Disorders: Results of an Open-Label Study

Jan K. Buitelaar, Rutger Jan van der Gaag, and Joost van der Hoeven

Published: February 15, 1998

Article Abstract

Background: We evaluated the efficacy and safetyof buspirone in the management of anxiety and irritability inchildren with pervasive developmental disorders (PDD).

Method: Twenty-two subjects, 6 to 17 years old,with DSM-III-R diagnosed PDD-NOS (N=20) or autistic disorder(N=2), were included. They were treated with buspirone in dosagesranging from 15 to 45 mg/day in an open-label trial lasting 6 to8 weeks. Responders continued buspirone treatment and werefollowed up for up to 12 months.

Results: Nine subjects had a marked therapeuticresponse and 7 subjects a moderate response on the ClinicalGlobal Impressions (CGI) scale after 6 to 8 weeks of treatment.Side effects were minimal, except for 1 patient who developedabnormal involuntary movements.

Conclusion: These results suggest that buspironemay be useful for treating symptoms of anxiety and irritabilityin children with PDD.

Volume: 59

Quick Links: Child and Adolescent , Populations

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...